Quote data as of 6:42 PM ET
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
PetMeds reported a difficult fiscal 2026, with full-year revenue falling 21.1% to $179 million and a net loss widening to $57.3 million, driven largely by a $26.7 million goodwill impairment charge.
The company rejected two unsolicited acquisition proposals ranging from $4.00 to $4.25 per share, opting to continue as an independent entity despite significant operational headwinds and a declining cost structure.
Cash reserves stand at $21.4 million, while the company highlights a new master services agreement with Rural King and focuses on stabilizing core business operations under Interim CEO Leslie Campbell.